SEC Form 4 · accession 0001140361-18-005581
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dhiren D'Silva
Officer — VP Irish & European Operations
Period of report
Feb 7, 2018
Accepted (ET)
Feb 7, 2018 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $23.53 | holding | — | — | — | — | Sep 15, 2025 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F4 | $10.40 | holding | — | — | — | — | Dec 14, 2026 | ADSs | 80,000 | 80,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs are represented by American Depositary Receipts.
- F2Represents 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 09/15/2015 grant date.
- F4Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
This filing constitutes a Form 4 exit filing for the Reporting Person as the Reporting Person is no longer subject to Section 16 under the Securities Exchange Act of 1934.